Clene Q2 net loss widens on higher other expenses
CLNN•Financing, runway and NDA timeline
Clene closed a $7 million stock offering and extended debt maturities to August 2027.
The company expects to submit an NDA for CNM-Au8 in ALS under the accelerated approval pathway in early Q4 2026. Clene said its cash resources are expected to provide an operating runway through late Q4 2026.
Quarterly loss widened on higher other expenses
Clene said its second-quarter net loss widened year over year, driven primarily by higher other expenses.
The company attributed the increase in net loss mainly to a rise in other expenses, including changes in the fair value of warrant and derivative liabilities and higher interest expense.
Regulatory preparation and lower administrative costs
Increased regulatory activities and NDA preparation contributed to higher expenses, partially offset by lower costs in some clinical programs.
General and administrative expenses fell due to lower legal, finance and accounting fees, and increased grant revenue.
